Halabi, S., Roy, A., Rydzewska, L., Godolphin, P., Parmar, M. K., Hussain, M., … Sweeney, C. J. (2022). 1375P Intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC). In Annals of Oncology (Vol. 33, pp. S1171–S1171). Elsevier BV. https://doi.org/10.1016/j.annonc.2022.07.1507

Halabi, S., A. Roy, L. Rydzewska, P. Godolphin, M. K. Parmar, M. Hussain, C. Tangen, et al. “1375P Intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).” In Annals of Oncology, 33:S1171–S1171. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.07.1507.

Halabi S, Roy A, Rydzewska L, Godolphin P, Parmar MK, Hussain M, et al. 1375P Intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC). In: Annals of Oncology. Elsevier BV; 2022. p. S1171–S1171.

Halabi, S., et al. “1375P Intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S1171–S1171. Crossref, doi:10.1016/j.annonc.2022.07.1507.

Halabi S, Roy A, Rydzewska L, Godolphin P, Parmar MK, Hussain M, Tangen C, Thompson IM, Xie W, Carducci MA, Smith M, Morris MJ, Gravis Mescam G, Dearnaley D, Verhagen P, Goto T, James ND, Buyse ME, Tierney J, Sweeney CJ. 1375P Intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC). Annals of Oncology. Elsevier BV; 2022. p. S1171–S1171.